Summary Information for: Elecsys & #xae; Anti-HBc IgM Immunoassay and Elecsys & #xae; PreciControl Anti-HBc IgM for use on the cobas e 411 Immunoassay AnalyzerJanuary 10, 2012 5:31 am | by U.S. Food & Drug Administration | News | Comments
Labeling, Approval Order, and Summary of Safety and Effectiveness for Elecsys® Anti-HBc IgM Immunoassay and Elecsys® PreciControl Anti-HBc IgM for use on the cobas e 411 Immunoassay Analyzer (P110031).
Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety RiskJanuary 9, 2012 6:30 am | by U.S. Food & Drug Administration | News | Comments
A packaging problem may result in a pill, tablet or caplet getting mixed in with a different prescription.
Novartis Consumer Health Over-The-Counter Products: Recall - Potential Presence of Foreign Tablets or Chipped or Broken Tablets or GelcapsJanuary 9, 2012 5:30 am | by U.S. Food & Drug Administration | News | Comments
Consumers are asked to either destroy or return unused product identified in the recall to Novartis.
The FDA's National Center for Toxicological Research (NCTR) has purchased a micro-sample viscometer, VISCOLab 5000, to better characterize and detect nanoscale materials. The agency's research involves the manipulation of biological buffers in saline solutions with tissue culture media...
The FDA should establish a new standard for premarket clearance to tell the difference between products that can be approved based on predicate devices alone and those that need more rigorous postmarket approval, says one legal expert.
A group of medical device experts from EU member states would oversee device regulation in the union, according to one proposal in a recent “roadmap” released by the European Commission’s Directorate-General for Health & Consumers.
Regulatory Harmonization Institute: First Not-For-Profit Organization Dedicated to Global Harmonization of Drug and Medical Device Regulatory RequirementsJanuary 5, 2012 5:24 am | News | Comments
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--The Regulatory Harmonization Institute, Inc. (RHI) an international, not-for-profit association dedicated to global harmonization of drug and medical device regulatory requirements, today announced the launch of its Web site, programs and initiatives...
Adverse consequences may include hypoxia, hypotension, bradycardia, cardiac arrest, organ damage, acute respiratory distress syndrome (ARDS), neurological deficits, or death.
Reason for Recall: Fretting corrosion at the electrical contact interface of certain metals was the root cause for erratic nitric oxide (NO) monitoring readings. Adverse consequences may include inadequate oxygen reaching the tissues in the body...
Devicemakers responding to unsolicited requests for off-label product information are urged to keep conversations private and specific to the requester’s inquiry, according to a new FDA draft guidance.
Concerns about the future of the FDA’s 510(k) process appear to have been put to rest with the year-end issuance of a draft guidance on evaluating substantial equivalence in 510(k)s.
Draft Guidance for Industry and Food and Drug Administration Staff - Medical Device Classification Product CodesDecember 30, 2011 3:31 am | by U.S. Food & Drug Administration | News | Comments
Since the May 28, 1976 Medical Device Amendments were passed, the Classification Regulation Panels (21 CFR 862-892) have been the basis for the Center for Devices and Radiological Health?s (CDRH) Classification Product Code structure and organization.
Ventilator may stop ventilating and result in life-threatening injury or death.
Reason for Recall: The AVEA ventilator can develop a failure where the ventilator activates a false Extended High Ppeak alarm, opens the safety valve and stops ventilating. Without health care professional intervention, patients may suffer...
Additional concentration of liquid acetaminophen marketed for â€œinfantsâ€ (160 mg/5 mL) is now available.
Salmonella can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.
Hair, clothing or jewelry can become entangled in the ShoulderFlex Massager and cause serious injury or even death from strangulation.
St. Jude Medical, Riata and Riata ST Silicone Endocardial Defibrillation Leads: Class 1 Recall - Failures with Lead InsulationDecember 21, 2011 3:31 am | by U.S. Food & Drug Administration | News | Comments
Premature insulation abrasion may cause the conductors to become externalized, which can cause serious adverse health consequences, including death.
Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First DoseDecember 20, 2011 10:31 am | by U.S. Food & Drug Administration | News | Comments
Patients with MS should not stop taking Gilenya without talking to their healthcare professional.
Guidance for Industry and Food and Drug Administration Staff - Enforcement Policy for Premarket Notification Requirements for Certain In Vitro Diagnostic and Radiology DevicesDecember 20, 2011 3:30 am | by U.S. Food & Drug Administration | News | Comments
This document is intended to describe FDA?s intent with regard to enforcement of premarket notification (510(k)) requirements for certain in vitro diagnostic and radiology devices under 21 CFR Part 807, Subpart E. FDA intends to propose the...
WASHINGTON, D.C. â€“ Representatives Edward J. Markey (D-Mass.), Diana DeGette (D-Colo.), Henry A. Waxman (D-Calif.), Jan Schakowsky (D-Ill.), and Rosa DeLauro (D-Conn.) today sent a letter to the Commissioner of the Food and Drug Administration (FDA) raising concerns about flaws...
Labeling, Approval Order, and Summary of Safety and Effectiveness for AtriCure Synergy Ablation System (P100046).
The AtriCure Synergy Ablation System is used to destroy (ablate) heart tissue that is beating abnormally. It includes the Synergy Ablation Clamp, a handheld surgical device that destroys the heart tissue that is grasped between the clamp?s jaws during...
A negative devices advisory panel opinion, based on inconsistencies in clinical trials, may jeopardize a hoped-for buy-in by St. Jude Medical for the CardioMEMS monitoring device for heart failure.
Devicemakers no longer need to meet a Jan. 1 Sunshine Act deadline for reporting payments to doctors and hospitals.